GTC Biotherapeutics (fka GTCB)

[DewDiligence]

>the reason why I ignored your claim that GTC Researchers can simply "engineer in" post-translational modifications is because its not that easy. Trust me, Ive engineered-in and engineered-out N-linked glycosylation signatures on multiple scaffolds. I would gather that its especially dicey for a metastable protein like a serpin, which is basically a molecular mousetrap waiting to catch a protease.<

If it’s hard to do, that plays right into GTC’s competitive strength, IMO. Scientific brainpower is clearly one thing that GTC does not lack.